<DOC>
	<DOC>NCT01588548</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and tolerability of AZD 1208 up to a maximum tolerated dose (MTD) and define the dose(s) for further clinical evaluation when given daily to patients with advanced solid malignancies including malignant lymphoma</brief_summary>
	<brief_title>Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma</brief_title>
	<detailed_description>A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD1208 in Patients with Advanced Solid Malignancies including Malignant Lymphoma</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients who have signed this Written Informed Consent Form after a full explanation about the participation in this study Patients aged 18 years or older Patients diagnosed with a solid malignant tumour or malignant lymphoma that is refractory to standard therapies or for which no standard therapies exist Patients with good physical conditions (you can walk and can look after yourself) within the last 2 weeks. Patients who have at least one lesion that can be accurately assessed Patients who have recently received or are receiving prohibited medications or treatments Patients who have any unresolved side effects of previous treatments Patients who have spinal cord compression or brain metastases Patients who have severe systemic diseases (e.g., uncontrolled hypertension, hepatitis B, hepatitis C and human immunodeficiency virus [HIV] infection) Patients with significant abnormal ECG findings</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Advanced solid malignancies</keyword>
	<keyword>Malignant lymphoma</keyword>
</DOC>